Earlier this month, Stada proposed a slate of four new directors--but now, as promised, its rebel shareholder is out with an alternative lineup.

Celgene’s best-selling drug Revlimid fell short in a lymphoma trial, putting its hopes for a $1 billion revenue boost in danger.

Eli Lilly isn’t expecting an easy drug pricing environment going forward. But never fear, investors: It’s expecting volume gains.

Amid intense hep C competition, Gilead reported plummeting Q2 sales for the megablockbuster franchise and slashed its full-year revenue forecast, putting more…

What’s a quick way to nab market share from a competitor? Roll out a superior product at the same price--and that’s what Shire’s confident it’s doing with dry…

Boehringer was hoping to get some more mileage out of targeted lung cancer med Gilotrif. But those hopes have been dashed by a data monitoring committee.

Worried that GlaxoSmithKline or AstraZeneca might pull up their U.K. roots in the wake of Brexit? Rest easy. Both companies are set to reassure the world this…

Pharma's gifts to politicians--one, in particular--have been in the spotlight since presidential candidate Hillary Clinton announced her VP pick Friday.

Roche won another reprieve in its fight againstthousands of Accutane safety claims. The drugmaker persuaded a New Jersey appeals court to overturn an $18M jury…